Just a few weeks after Rhythm Pharmaceuticals $RYTM snagged an FDA OK for setmelanotide in 3 rare genetic disorders that trigger obesity, the biotech is struggling to make a good case for a crucial market expansion.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,